Clinical and Experimental Dermatology · 2023 · 10 citations · 5 references
MedicineDermatologyImmunologyClinical ImmunologyCutaneous OncologyImmunotherapyAtopic DermatitisCutaneous LymphomaImmunopathology Of SkinInflammatory DermatosesInflammatory Skin DiseasesInflammatory Skin DisordersAtopic Dermatitis ImmunopathologyAtopic Dermatitis PharmacotherapyCutaneous T-cell Lymphoma ImmunopathologyCutaneous T-cell Lymphoma TreatmentDermatologic Adverse EventsMonoclonal Antibody InfusionSézary SyndromeTertiary Care Organization
Dupilumab is a monoclonal antibody targeting the interleukin-4 and -13 signalling pathway, and which is proven to be highly effective and safe in atopic dermatitis (AD). Its possible role in treating or inducing cutaneous T-cell lymphomas (CTCLs) has not yet been fully clarified, as several case reports seem to point not only at its beneficial effects but also at a possible pathogenetic role in mycosis fungoides and Sézary syndrome. We present data collected from a cohort of 995 patients with classic or prurigo nodularis-like AD who received dupilumab and were followed longitudinally for a mean period of 25.1 months after first administration to investigate a possible correlation between dupilumab and CTCL development.
5
Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation
Larisa J. Geskin, Sara Viragova, Donna B. Stolz et al. · Blood · 2015 · 162 citations · Full text
Medicine, Dermatology, Oncology +9
Cutaneous T-cell Lymphoma and Concomitant Atopic Dermatitis Responding to Dupilumab
Nicholas Mollanazar, Kevin T. Savage, Bobak Pousti et al. · Cutis · 2020 · 30 citations · Full text
Medicine, Dermatology, Immunology +17